These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 18771053)
1. Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment. Spire B; Carrieri P; Sopha P; Protopopescu C; Prak N; Quillet C; Ngeth C; Ferradini L; Delfraissy JF; Laureillard D Antivir Ther; 2008; 13(5):697-703. PubMed ID: 18771053 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort. Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study. Zoufaly A; Fillekes Q; Hammerl R; Nassimi N; Jochum J; Drexler JF; Awasom CN; Sunjoh F; Burchard GD; Burger DM; van Lunzen J; Feldt T Antivir Ther; 2013; 18(5):681-90. PubMed ID: 23502762 [TBL] [Abstract][Full Text] [Related]
4. Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. Meresse M; Carrieri MP; Laurent C; Kouanfack C; Protopopescu C; Blanche J; Cohen J; Laborde-Balen G; Aghokeng AF; Spire B; Moatti JP; Delaporte E; Boyer S; Antivir Ther; 2013; 18(1):29-37. PubMed ID: 23358393 [TBL] [Abstract][Full Text] [Related]
5. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. BREATHER (PENTA 16) Trial Group Lancet HIV; 2016 Sep; 3(9):e421-e430. PubMed ID: 27562743 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716 [TBL] [Abstract][Full Text] [Related]
7. Impact of low-level viraemia on virological failure among Asian children with perinatally acquired HIV on first-line combination antiretroviral treatment: a multicentre, retrospective cohort study. Sudjaritruk T; Teeraananchai S; Kariminia A; Lapphra K; Kumarasamy N; Fong MS; Hansudewechakul R; Bunupuradah T; Ly PS; Nallusamy RA; Sohn AH; Sirisanthana V; J Int AIDS Soc; 2020 Jul; 23(7):e25550. PubMed ID: 32628816 [TBL] [Abstract][Full Text] [Related]
8. High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. Isaakidis P; Raguenaud ME; Te V; Tray CS; Akao K; Kumar V; Ngin S; Nerrienet E; Zachariah R J Int AIDS Soc; 2010 Mar; 13():11. PubMed ID: 20302672 [TBL] [Abstract][Full Text] [Related]
9. Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. Chendi BH; Okomo Assoumou MC; Jacobs GB; Yekwa EL; Lyonga E; Mesembe M; Eyoh A; Ikomey GM BMC Infect Dis; 2019 Feb; 19(1):194. PubMed ID: 30808298 [TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884 [TBL] [Abstract][Full Text] [Related]
14. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. Ferradini L; Laureillard D; Prak N; Ngeth C; Fernandez M; Pinoges L; Puertas G; Taburet AM; Ly N; Rouzioux C; Balkan S; Quillet C; Delfraissy JF AIDS; 2007 Nov; 21(17):2293-301. PubMed ID: 18090277 [TBL] [Abstract][Full Text] [Related]
15. HIV viral suppression in TREAT Asia HIV Observational Database enrolled adults on antiretroviral therapy at the Social Health Clinic, the National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia. Boettiger DC; Khol V; Durier N; Law M; Sun LP Antivir Ther; 2016; 21(8):725-730. PubMed ID: 27124891 [TBL] [Abstract][Full Text] [Related]
16. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA; Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460 [TBL] [Abstract][Full Text] [Related]
17. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA; Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068 [TBL] [Abstract][Full Text] [Related]